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Abstract: One of the most feared transfusion accident is the haemolytic reaction. A majority of countries impose a 
compatibility test before each transfusion, at the patient’s bedside or in laboratory. Regardless of the test 
performed, it does not prevent human errors and nothing ensures an “error free” procedure. Complete 
crossmatch is the only test ensuring a complete blood compatibility between donors and patients. It relies on 
the direct or indirect detection of agglutinations which occur when the patient’s plasma is mixed with the red 
cells to be transfused. It requires extracting plasma. The work described here will help avoid all the 
immunologic incompatibilities by the use of a compatibility test without plasma extraction. It relies on an 
immuno- biochip technology in a microfluidic environment with fluorescence detection. This position paper 
presents preliminary results obtained with artificial samples together with comments on the state of industrial 
competition and the new device market positioning. 
1 INTRODUCTION 
In France every year, more than 3 million labile blood 
products, 80% of which were red blood cells (RBC), 
are given to more than 550 000 patients (ANSM 
2016). French health institutions have seen a rise in 
deliveries of RBC of + 26.3% in total between 2000 
and 2014 (EFS, 2014). In 2016, according to the 
haemovigilance report by ANSM (National Agency 
for Drug Safety), 6780 adverse effects in recipients 
(AER) related to transfusion were reported. In total, 
255 adverse effects in receivers related to transfusion 
were recorded due to immunological incompatibility. 
The situation seems to be similar in countries with the 
same level of safety as France.  
In most countries, a crossmatch (a compatibility 
test between blood for transfusion and the receiver's 
blood) is carried out in a laboratory prior to 
transfusion. The current techniques for carrying out a 
crossmatch are either manual, with blood reagents 
and samples being mixed in tubes or being placed on 
gel columns before centrifuging, or automated. As far 
as these automated systems are concerned, the 
analyzers may only be used in a laboratory and the 
analyses are time consuming which can delays the 
delivery of the blood product. This test is even 
avoided in some emergency situations. 
Currently, the final pre-transfusion test at the 
patient's bedside consists mainly of an identity check 
(identity of the red cell concentrate (RCC) and 
identity of the patient). This method cannot guarantee 
that there will be no transfusion accident because 
50% of the reported adverse effects are due to human 
error, most of them being “wrong blood in tube” 
(SHOT 2011). Therefore, in spite of increasingly 
effective safety systems, it is currently impossible to 
eliminate entirely the risks due to human error, both 
in the laboratory and at the time of the transfusion. 
 These errors highlight the need for a pre-transfusion 
analyzer which does not require pre-treatment 
(plasma extraction, and/or centrifugation) in order to 
limit human manipulation and subsequent errors.  
Some research was carried out in order to make 
this process ultimately safe. They are mainly based on 
gel agglutination techniques which requires plasma 
extraction (Cid et al. 2006; Longston et al. 1999) or 
SPR (Malomgre et al. 2009; Quinn et al. 2000; 
Houngkamhang et al. 2013). More recently, Long-
Range Surface Plasmon-Polaritons have been 
suggested to detect selectively captured red blood 
cells using specific surface chemistry (Krupin et al. 
2014). This system can capture red blood cells in a 
sample with a very low cell concentration. The initial 
dilution of the sample is carried out in a buffer with a 
controlled refractive index. Blood samples must then 
be prepared which is not an improvement compared 
to current crossmatch. Test plates and image 
processing have also been proposed for phenotyping 
blood groups (Ferraz et al. 2010). Micro fluidics 
coupled with optical fibers are reported in 
(Ramasubramanian et al. 2009). A while ago, we 
proposed the use of functionalized biochips for ABO 
and rhesus compatibility tests (Charrière et al. 2015, 
Wacogne et al. 2017). 
Except the gel agglutination method which 
requires samples preparation, the other techniques 
could allow for blood grouping but not a direct 
compatibility check between the RCC to be 
transfused and the patient. The idea developed in this 
position paper arose from the fact that incompatible 
antibodies present in the patient’s blood bind to red 
cells to be transfused and may lead, more or less 
rapidly, to the lyses of RCC. 
Therefore, our proposal is to use a single biochip 
onto which red cells to be transfused are trapped. 
Subsequently, patient’s whole blood is applied onto 
the biochip and possibly present irregular antibodies 
react with the RCC. Finally, fluorescent anti-IgGs 
antibodies are used in order to allow rapid optical 
detection. Using such an architecture allows detecting 
any erythrocytic immunological incompatibilities 
without extracting patient’s plasma. In this way, this 
very rapid test can be performed by nonspecifically 
trained people, with a reduced and non prepared 
receiver’s blood sample. 
 This principle will be described in part 2 of this 
communication together with the actual biological 
model used to demonstrate a first proof of concept. A 
description of the experimental set-up and results 
obtained using fluorescence spectroscopy will be the 
subject of part 3. In part 4 and in line with the scope 
of a position paper, we will comment on the state of 
industrial competition and the new devices market 
positioning. 
2 GENERAL PRINCIPLE AND 
ACTUAL IMMUNOLOGICAL 
MODEL 
2.1 Biochip principle 
The method we propose is depicted in figure 1 in the 
case of non-compatible transfusion. Red cells from 
the RCC to be transfused are applied to the biochip 
previously grafted with antibodies directed to a high-
incidence antigen (figure 1(a)). After rinsing, a RCC 
layer is formed at the biochip surface. 
 
Figure 1: Principle of the blood-to-blood immunological 
compatibility test biochip. 
Patient’s whole blood is directly injected onto this 
surface (figure 1(b)). Antigen/antibody reactions 
occur when RCC exhibit an antigen which is 
complementary of an antibody present in the patient’s 
blood (irregular IgGs in this case). After rinsing, 
elements which have not reacted with the red cells 
layer are evacuated. 
Then, a solution of fluorescent anti-IgGs 
antibodies is applied to the biochip (figure 1(c)). 
These antibodies react with the patient’s irregular 
antibodies forming a fluorescent layer at the biochip’s 
surface. The latter is eventually detected using 
conventional fluorescence techniques. 
In this example, irregular IgGs have been 
considered. However, incompatibility may be due to 
presence of IgM in the patient’s whole blood (case of 
the ABO incompatibility). In this case, and this is not 
shown in this proof of concept communication, 
fluorescent anti IgMs antibodies should be employed. 
In order to address any incompatibility situation, the 
ideal sensor should be adapted to the presence of both 
IgGs and IgMs. A way of doing would be to use a 
mixture of fluorescent IgGs and IgMs antibodies. The 
 fluorescent labels could be chosen in such a way that 
both exhibit the same excitation wavelength but 
different emission spectra. Here, a simple 
fluorescence spectrum fitting would furthermore 
indicate which kind of immuno-incompatibility 
arose. 
2.2 Immunological model 
In this model, RCC are captured on the biochip by 
means of anti Kell IgMs (figure 2). The KEL:2 
antigen (cellano) is present at the red cell surface of 
about 99.6% of the population. Therefore, for this 
proof of concept, the anti Kell IgMs are considered 
universal. In the future, we will have to find a red cell 
capture method which also works for the remaining 
0.4% of the population. 
 
Figure 2: Immunological model used in this proof of 
concept. 
In this example, red cells are Lub positive and Jka 
negative. For the positive test, a solution of irregular 
anti-Lub IgG antibodies is applied to the RCC 
immobilized on the biochip. In the same manner, a 
solution of anti-Jka antibodies is used for the negative 
test. When antigen-antibody reactions occur, 
antibodies bind to the red cells surface. 
After rinsing, FITC coupled anti-IgGs antibodies 
are applied to the biochips. They react with the 
irregular antibodies possibly present at the RCC 
surface. In a positive test, a large amount of FITC 
coupled antibodies is present and a strong 
fluorescence signal is detected. On the contrary in a 
negative test, only non-specific interactions occur 
leading to a weak fluorescence signal. 
For these experiments, commercially available 
irregular antibodies were used (Bio-Rad). Further 
experiments will be conducted with whole blood. 
3 EXPERIMENTAL SET-UP AND 
PRELIMINARY RESULTS 
3.1 Biochemical reactions 
Immunological reactions described in figure 2 were 
performed using the fluidic system of our SPRi 
apparatus (SPRi-Plex imager, Horiba Scientific) at 
37°C with a MLB2 (Bio-Rad) running buffer. 
Biochips were prepared according to the process 
described in (Charriere et al. 2015) without RSA 
saturation. Anti-Kell IgMs (dilution 1/10 in acetate 
buffer, 10 mM and pH 4.5) were grafted onto 
biochips. 
200 µL of pouch’s red cells were injected onto the 
biochips at 20 µL/min. After rinsing, 200 µL, 
irregular antibodies (anti-Lub and anti-Jka, 1/10 in 
MLB2, BioRad) were injected at 20 µL/min. FITC 
anti-IgGs (Sigma) were injected (200 µL, 20µL/min, 
1/25 in MLB2). 
Complex red cells / antibodies were finally fixed 
using a 0.5% glutaraldehyde solution. Biochips were 
wetted with MLB2 buffer and protected with cover 
slits before fluorescence measurements. 
3.2 Fluorescence measurement set-up 
FITC was excited at 488 nm using an Oxxius 488-50-
COL-PP laser. Excitation light was injected into a 
fluorescence beam-splitter as shown in figure 3.  
This beam-splitter (Doric Lenses) is equipped 
with excitation and emission filters together with a 
dichroic mirror (respectively FF01-488/10-25, 
BLP01-488R-25 and FF500-Di01-2536). 
Fluorescence spectra were recorded using a QE-Pro 
spectrometer (Ocean Optics). 
 
Figure 3: Fluorescence beam-splitter used in these 
experiments. 
 3.3 Additional fluorescence 
This kind of beam-splitter is usually designed to be 
used with optical fibres. Because we use it in an open 
beam configuration, additional fluorescence signals 
are observed due to multiple reflexions in the beam-
splitter (figure 4). This additional fluorescence is 
mainly generated by the epoxy resin used to glue 
optical elements in the beam-splitter. 
 
Figure 4: Origin of the additional fluorescence. 
The shape of the additional fluorescence was 
recorded and used as explained in the next section. 
3.4 Experimental results 
Overall, 18 measurements were performed with 2 
demonstration biochips (7 random places on the 
positive biochip and 11 on the negative). 
Fluorescence spectra were recorded as above 
mentioned. In order to isolate the contribution of the 
FITC signal from the whole recorded spectrum a 
simple fitting was employed. Indeed, we recorded the 
shape of the additional fluorescence and we know the 
shape of the FITC emission spectrum. Fitting the 
experimental spectra with these 2 shapes allows 
separating the contribution of the FITC from the 
contribution of the additional fluorescence. Figure 
5(a) shows an example of spectrum recorded with the 
positive biochip. 
In this figure, the green shape corresponds to the 
FITC while the grey shape correspond to the 
additional fluorescence. It can be seen that the fitting 
efficiently reproduces the recorded spectra. The 
feature reported on the right of the spectra represents 
the standard deviation of the difference between the 
experimental spectrum and the fitted one. It is an 
estimation of the fitting accuracy. It is clearly 
observed that the signal due to the FITC (about 10000 
levels) is much greater than the signal of the 
additional fluorescence. 
In figure 5(b), we present a spectrum obtained 
with the negative biochip. Here the shape of the 
additional fluorescence is clearly visible. 
 
Figure 5: Fluorescence spectra of: (a) positive biochip, (b) 
negative biochip. 
As previously mentioned, 18 spectra were 
recorded. Table 1 summarizes the levels of FITC and 
additional fluorescence obtained at each places of the 
biochips. 
Table 1: Summary of the fluorescence levels obtained with 
the 18 measurements on 2 biochips (1 positive, 1 negative). 
Type Spectra N° FITC Add. std 
P
o
si
ti
v
e
 
QEP003631_11 12525 757 0.61 
QEP003631_12 7470 766 0.39 
QEP003631_13 8419 702 0.64 
QEP003631_14 11261 797 0.37 
QEP003631_15 12355 732 0.58 
QEP003631_16 13935 702 0.7 
QEP003631_17 1784 575 2.27 
N
eg
at
iv
e 
QEP003631_02 0 666 1.79 
QEP003631_03 0 697 1.72 
QEP003631_04 198 697 1.31 
QEP003631_05 198 697 1.31 
QEP003631_06 270 657 1.78 
QEP003631_20 577 672 1.15 
QEP003631_21 537 668 1.51 
QEP003631_22 8 664 1.65 
QEP003631_23 24 663 1.78 
QEP003631_24 6 732 1.73 
QEP003631_25 74 750 2.06 
 
 From these data, it can be seen that the level of 
additional fluorescence is relatively constant (700±50 
levels). Also, FITC levels of the positive biochip is 
always much larger (except for the QEP003631_17 
 spectrum). It is however possible to define a threshold 
above which a biochip is considered positive. This is 
shown in figure 7 where a threshold at 1300 levels is 
reported. 
 
Figure 7: Definition of a positive threshold. 
This figure shows that the experimental set-up can 
be drastically simplified as a simple photodiode can 
be used to detect positive biochips. This would make 
the final device cost-effective and would ensure its 
use in a large number of situations. 
 
Figure 8: Extracting a weak FITC response using spectral 
fitting. 
However, the use of fluorescence spectroscopy 
may prove to be extremely useful in the case of weak 
antigen-antibody affinity or weak concentration of 
irregular antibodies. In some cases indeed, even a 
very low antibody concentration can lead to severe 
consequences for the patient (for example the anti-
Jka). The interest of fluorescence spectroscopy is 
illustrated in figure 8 which reproduces results 
obtained with the QEP003631_20 spectrum. This 
demonstrates that a simple fitting can extract a weak 
level of FITC signal from a spectrum possibly 
recognized as negative. Importantly, it must be noted 
that figure 8 does not represent a weak affinity/avidity 
situation but a case of non-specific interaction at the 
place where the spectrum was recorded. 
To conclude this experimental section, this work 
represents the preliminary results demonstrating that 
the immuno-biochip technology can be used to 
perform a complete blood compatibility test without 
plasma extraction. Further experiments are still 
required with a large range of irregular antibodies 
before considering a clinical trial on a larger scale. 
4 MARKET POSITIONING 
In countries with a safe transfusion system (80% of 
wealthy countries and 60% of averagely wealthy 
countries), the compatibility check is carried out 
either in the laboratory or at the patient's bedside, or 
both in some cases.  
In the laboratory, ABO grouping of RCC and the 
patient are carried out by analysers (Bio-Rad, 
Diagast, HTZ, Dia Pro, Grifols). The current 
techniques for carrying out a crossmatch or an 
irregular antibody screening are either manual, with 
blood reagents and samples being mixed in tubes or 
being placed on gel columns before centrifuging (e.g. 
Across Gel® Cross Match, from Dia Pro or ID-Card 
50531 from Bio-Rad), or automated (e.g. the Qwalys 
analysers from Diagast). The analysers require 
additional time-consuming manual operations, (blood 
centrifugation for example) which may increase the 
risk of errors. Furthermore, they are oversized for 
technical platforms or small size laboratories.   
To mitigate these risks, some countries, including 
France, have formalised a final ABO compatibility 
check at the patient's bedside (ABO compatibility 
charts from Bio-Rad, Diagast). This check requires 
qualified and regularly trained staff, is limited to 
ABO compatibility and cannot prevent certain human 
errors in terms of allocation, realization or 
interpretation. 
During the work presented here, a market 
research carried out by a specialist firm and 
companies with a potential interest, found that the 
biochip technology, is of major interest. There is 
nothing similar in this enormous market. This market 
research also showed that the final control of just 
ABO compatibility on a biochip would not currently 
be sufficient to penetrate the world market because of 
the practices in place in most countries. The 
companies we approached strongly advised 
increasing the added value of this biochip by 
broadening its application to carry out crossmatch, 
what we did. Given this international perspective, the 
two initial patents we published (Pazart et al. 2001-1, 
2011-2) were also broadened and recorded in Europe, 
North America and in “BRIC” countries. 
 5 CONCLUSION 
We have presented the proof of concept of a biochip 
potentially able to perform a blood-to-blood 
immunological compatibility test in a simple fluidic 
environment. It relies on a single biochip onto which 
red cells to be transfused are trapped. Subsequently, 
patient’s whole blood is applied onto the biochip and 
possibly present incompatible antibodies react with 
the RCC. Eventually, fluorescent anti-IgGs 
antibodies are used in order to allow rapid optical 
detection. 
Fluorescence spectroscopy experiments showed 
that irregular antibodies can easily be detected. Here, 
we used solutions of irregular antibodies. The next 
steps will consist in multiplying the types of irregular 
antibodies and to perform experiments with whole 
blood obtained from donors. Potentially, a simple 
photodiode based detection can be used. This would 
allow using a compact device which can be used 
either by trained or non trained medical staff. 
However, the use of fluorescence spectroscopy in a 
more complex set-up can probably lead to the 
detection of weak but potentially dangerous 
incompatibilities. 
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